RxDoctor Payments Data

Alejandro Garciasalas, MD

Internal Medicine · Beaufort, SCNPI 1811209877

Payments from drug & device makers

$1,389in general payments, 2019–2025

Across 79 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$237
  • AstraZeneca$230
  • Novo Nordisk$159
  • Amgen$100
  • Exact Sciences$87
  • Pfizer$79
  • plus $496 from 15 others

What the payments were for

  • Food & beverage$1,389100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,389 in reported general payments places this provider in the 70th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$250,498
Medicare patients
640
Services billed
3,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$143,235
OzempicSemaglutide72$89,559
MounjaroTirzepatide77$86,261
JanuviaSitagliptin Phosphate53$72,434
XareltoRivaroxaban36$49,459
JardianceEmpagliflozin19$32,308
TrulicityDulaglutide20$26,935
LinzessLinaclotide29$22,459
MyrbetriqMirabegron28$19,819
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$15,106
MultaqDronedarone Hcl11$14,845
Fenofibrate94$13,008
FarxigaDapagliflozin Propanediol15$10,552
Atorvastatin Calcium834$9,370
Tresiba Flextouch U-100Insulin Degludec13$9,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$143,235112 claims
Lilly USA, LLCMounjaro, Trulicity$237$113,19697 claims
Novo NordiskOzempic$159$89,55972 claims
MerckJanuvia$23$72,43453 claims
Boehringer IngelheimJardiance$36$32,30819 claims
AbbVieLinzess$61$22,45929 claims
Astellas Pharma US IncMyrbetriq$33$19,81928 claims
AstraZenecaFarxiga$230$10,55215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Beaufort

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →